^
Association details:
| Biomarker: | MSI-H/dMMR + TMB-H |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
Published date:
06/01/2021
Excerpt:
We present a rare case of prolonged response to the combination of pembrolizumab and trastuzumab in a woman with heavily pretreated, human epidermal growth factor receptor 2 (HER2)–positive, metastatic BC (mBC) that was found to be MSI-H and TMB-H.
DOI:
10.1200/PO.20.00361
